Literature DB >> 31260163

Metabolism and Gut Microbiota in Cancer Immunoediting, CD8/Treg Ratios, Immune Cell Homeostasis, and Cancer (Immuno)Therapy: Concise Review.

Irina Kareva1.   

Abstract

The concept of immunoediting, a process whereby the immune system eliminates immunogenic cancer cell clones, allowing the remaining cells to progress and form a tumor, has evolved with growing appreciation of the importance of cancer ecology on tumor progression. As cancer cells grow and modify their environment, they create spatial and nutrient constraints that may affect not only immune cell function but also differentiation, tipping the balance between cytotoxic and regulatory immunity to facilitate tumor growth. Here, we review how immunometabolism may contribute to cancer escape from the immune system, as well as highlight an emerging role of gut microbiota, its effects on the immune system and on response to immunotherapy. We conclude with a discussion of how these pieces can be integrated to devise better combination therapies and highlight the role of computational approaches as a potential tool to aid in combination therapy design. Stem Cells 2019;37:1273-1280. ©AlphaMed Press 2019.

Entities:  

Keywords:  Combination therapies; Gut microbiota; Homeostasis; Immunoediting; Immunometabolism

Year:  2019        PMID: 31260163     DOI: 10.1002/stem.3051

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  10 in total

1.  The age of immunotherapy-Celebrating STEM CELLS' contribution to understanding mechanisms of immune system development and modulation.

Authors:  Jan A Nolta
Journal:  Stem Cells       Date:  2020-01       Impact factor: 6.277

Review 2.  Metabolic profiles of regulatory T cells in the tumour microenvironment.

Authors:  Disha Rao; Fabienne Verburg; Kathrin Renner; Daniel S Peeper; Ruben Lacroix; Christian U Blank
Journal:  Cancer Immunol Immunother       Date:  2021-02-12       Impact factor: 6.968

3.  Immune microenvironment characteristics and their implications for immune checkpoint inhibitor efficacy in HER2-overexpressing gastric cancer.

Authors:  Shuyi Cen; Haimiao Xu; Zhen Liu; Rongjie Zhao; Hongming Pan; Weidong Han
Journal:  Clin Exp Immunol       Date:  2022-05-12       Impact factor: 5.732

Review 4.  Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment.

Authors:  Varun Sasidharan Nair; Reem Saleh; Salman M Toor; Farhan S Cyprian; Eyad Elkord
Journal:  Cancer Immunol Immunother       Date:  2021-02-03       Impact factor: 6.968

Review 5.  Celiac Disease and the Microbiome.

Authors:  Francesco Valitutti; Salvatore Cucchiara; Alessio Fasano
Journal:  Nutrients       Date:  2019-10-08       Impact factor: 5.717

Review 6.  Radiotherapy and the gut microbiome: facts and fiction.

Authors:  Jing Liu; Chao Liu; Jinbo Yue
Journal:  Radiat Oncol       Date:  2021-01-13       Impact factor: 3.481

Review 7.  The cancer metabolic reprogramming and immune response.

Authors:  Longzheng Xia; Linda Oyang; Jinguan Lin; Shiming Tan; Yaqian Han; Nayiyuan Wu; Pin Yi; Lu Tang; Qing Pan; Shan Rao; Jiaxin Liang; Yanyan Tang; Min Su; Xia Luo; Yiqing Yang; Yingrui Shi; Hui Wang; Yujuan Zhou; Qianjin Liao
Journal:  Mol Cancer       Date:  2021-02-05       Impact factor: 27.401

8.  Overexpression of Pyruvate Dehydrogenase Kinase-3 Predicts Poor Prognosis in Urothelial Carcinoma.

Authors:  Yu-Hsuan Kuo; Ti-Chun Chan; Hong-Yue Lai; Tzu-Ju Chen; Li-Ching Wu; Chung-Hsi Hsing; Chien-Feng Li
Journal:  Front Oncol       Date:  2021-09-13       Impact factor: 6.244

9.  Effects of dihydroartemisinin on the gut microbiome of mice.

Authors:  Yanyan Liu; Yanhong Yang; Yuting Lei; Lanxiang Yang; Xueying Zhang; Jian Yuan; Zili Lei
Journal:  Mol Med Rep       Date:  2020-05-20       Impact factor: 2.952

10.  HIF1α-Dependent Metabolic Signals Control the Differentiation of Follicular Helper T Cells.

Authors:  Lin Dong; Ying He; Shuping Zhou; Yejin Cao; Yan Li; Yujing Bi; Guangwei Liu
Journal:  Cells       Date:  2019-11-17       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.